{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5e81d0643b9a0dd40f9937b2/690b7478b27ff20ceb1d7a93?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"What factors influence BTKi + BCL-2i treatment selection for patients with CLL? ","description":"<p>The Lymphoma Hub was pleased to speak to Francesc Bosch, Vall d'Hebron Barcelona Hospital Campus, Barcelona, ES. We asked, what factors influence Bruton’s tyrosine kinase inhibitor (BTKi) + B-cell lymphoma 2 inhibitor (BCL-2i) treatment selection for patients with chronic lymphocytic leukemia (CLL)? </p><p><br></p><p>This educational resource is independently supported by Johnson &amp; Johnson. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.</p>","author_name":"Scientific Education Support"}